EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR-TKI, exhibits favorable safety and excellent central nervous system (CNS) penetration and is recommended as the new first-line therapy of advanced NSCLC patients in routine practice (Leonetti et al., 2019; Huang et al., 2020).